Sun L, et al. - In this study, patients who received rituximab [RTX, n=60 (48%)] during the index presentation with acute immune-mediated thrombotic thrombocytopenic purpura (iTTP) were compared to those who did not in terms of relapse rates, to assess the efficacy of RTX in mitigating relapse risk in these subjects. Researchers used a multi-institutional cohort including consecutive adult patients with iTTP (n=124). Relapse was noted in 34 patients (27%). For RTX-treated and untreated patients, the observed median time to relapse was 3.71 (interquartile range, 1.75-4.9) and 1.33 (interquartile range, 0.43-2.35) years, respectively. Presenting in iTTP relapse, age younger than 25 years, and non-O blood group were the factors that showed independent relation to an increased risk for subsequent relapse. Relapse could be prevented for short-term with RTX treatment.